Financial Gravity Companies Inc. Invests $1.79 Million in Moderna, Inc. $MRNA

Financial Gravity Companies Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 64,859 shares of the company’s stock, valued at approximately $1,789,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. S Bank Fund Management Ltd bought a new position in Moderna in the first quarter valued at approximately $25,000. Atlantic Union Bankshares Corp acquired a new stake in shares of Moderna in the 2nd quarter valued at approximately $26,000. TD Private Client Wealth LLC grew its stake in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after buying an additional 743 shares in the last quarter. Whittier Trust Co. bought a new position in shares of Moderna in the second quarter valued at $28,000. Finally, SVB Wealth LLC bought a new stake in Moderna during the first quarter worth $28,000. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MRNA. Citigroup decreased their price objective on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Morgan Stanley lifted their price target on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. UBS Group dropped their price objective on Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, October 23rd. Bank of America cut their price objective on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, November 10th. Finally, Barclays decreased their target price on Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $35.85.

Moderna Trading Down 0.8%

Shares of MRNA stock opened at $24.77 on Friday. The stock has a market cap of $9.68 billion, a P/E ratio of -3.07 and a beta of 2.02. Moderna, Inc. has a 1 year low of $23.04 and a 1 year high of $48.92. The stock has a 50 day simple moving average of $25.92 and a 200 day simple moving average of $27.07.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company’s revenue was down 45.4% on a year-over-year basis. During the same quarter last year, the company earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. Analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.